TD Cowen 46th Annual Health Care Conference

3/3/2026 | 3:10pm ET

Webcast Link

Leerink Partners Global Healthcare Conference

3/10/2026 | 1:40pm ET

Webcast Link

Barclays 28th Annual Global Healthcare Conference

3/11/2026 | 1-on-1 meetings

Events & Presentations

  • Barclays 28th Annual Global Healthcare Conference

    03/11/2026 | 9:00pm PDT / 12:00am EDT

  • Leerink Partners Global Healthcare Conference

    03/10/2026 | 10:40am PDT / 1:40pm EDT

    Watch the webcast

  • TD Cowen 46th Annual Health Care Conference

    03/03/2026 | 12:10pm PST / 3:10pm EST

    Watch the webcast
View all events

Financial Reports and Filings

Date Filing Title Downloads
03/09/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
03/04/2026 EFFECT EFFECT RTF XLS PDF HTML XBRL
03/04/2026 424B3 Form of prospectus reflecting facts events constituting substantive change from last form RTF XLS PDF HTML XBRL
03/02/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
02/27/2026 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
02/24/2026 S-3 Simplified registration form RTF XLS PDF HTML XBRL
02/24/2026 10-K Annual report which provides a comprehensive overview of the company for the past year RTF XLS PDF HTML XBRL
02/23/2026 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
02/11/2026 SCHEDULE 13G/A SCHEDULE 13G/A - Description RTF XLS PDF HTML XBRL
02/09/2026 SCHEDULE 13G SCHEDULE 13G - Description RTF XLS PDF HTML XBRL
View all filings

Latest News

Myriad Commercially Launches Precise MRD with Select Community Oncologists Thumbnail

Myriad Commercially Launches Precise MRD with Select Community Oncologists

Mar 02, 2026 | Products

Read more
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests Thumbnail

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Feb 24, 2026 | Products

Read more
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution Thumbnail

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Feb 23, 2026 | Corporate | Financial

Read more
View all news releases

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

Read our QICR report

Quality, Innovation and Corporate Responsibility Report

Myriad Genetics has a strong commitment to operational excellence, innovation and being a good corporate partner. Our dedication to these important issues serve as the foundation to achieving our mission of advancing health and well-being for all.

Learn more about the actions we’re taking in quality, innovation, and corporate responsibility.

Read our QICR report